Research round-up

Abstract

In a proof of concept study, Domany and colleagues assessed 1 mg/kg oral ketamine for treatment-resistant depression. In this randomised trial, participants (n=41) received active treatment or placebo three times per week for 21 days. The decrease in depression symptoms compared with baseline was significant in the ketamine group at all time points assessed up to day 21 (p<0·05). In the placebo group, a significant decrease in symptom score was only apparent 40 mins after dosing. At day 21, the reduction in depression symptom score was lower in the ketamine group than in the placebo group (p<0·001), with six (27%) of 22 participants in the active treatment group achieving remission versus none in the placebo group (p<0·05). After first administration of study medication, six (40%) of 15 participants in the ketamine group and two (18%) of 11 participants in the placebo group had a transient increase in systolic blood pressure greater than 20 mmHg (p=0·23 for comparison). Efficacy and cost-effectiveness of therapist-guided internet cognitive behavioural therapy for paediatric anxiety disorders: a single-centre, single-blind, randomised controlled trialICBT is an efficacious and cost-effective treatment for paediatric anxiety disorders that should be considered for implementation in routine clinical care. Full-Text PDF Gender differentials and state variations in suicide deaths in India: the Global Burden of Disease Study 1990–2016India's proportional contribution to global suicide deaths is high and increasing. SDR in India is higher than expected for its Socio-Demographic Index level, especially for women, with substantial variations in the magnitude and men-to-women ratio between the states. India must develop a suicide prevention strategy that takes into account these variations in order to address this major public health problem. Full-Text PDF Open Access